RU2018145945A - Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма - Google Patents

Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма Download PDF

Info

Publication number
RU2018145945A
RU2018145945A RU2018145945A RU2018145945A RU2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A RU 2018145945 A RU2018145945 A RU 2018145945A
Authority
RU
Russia
Prior art keywords
lys
ser
asp
seq
thr
Prior art date
Application number
RU2018145945A
Other languages
English (en)
Russian (ru)
Other versions
RU2018145945A3 (enExample
Inventor
Клод КАРЕЛЛИ
Кристель ВЕТУ
Рафаэль ПАОЛИНИ
Original Assignee
Регулаксис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регулаксис filed Critical Регулаксис
Publication of RU2018145945A publication Critical patent/RU2018145945A/ru
Publication of RU2018145945A3 publication Critical patent/RU2018145945A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018145945A 2016-06-10 2017-06-09 Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма RU2018145945A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174056.8 2016-06-10
EP16174056 2016-06-10
PCT/EP2017/064196 WO2017212057A1 (en) 2016-06-10 2017-06-09 Peptides for the treatment of osteoarthritis

Publications (2)

Publication Number Publication Date
RU2018145945A true RU2018145945A (ru) 2020-07-10
RU2018145945A3 RU2018145945A3 (enExample) 2020-07-10

Family

ID=56132793

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018145945A RU2018145945A (ru) 2016-06-10 2017-06-09 Пептид для лечения остеоартрита, фармацевтическая композиция, лекарственное средство, единичная дозированная форма

Country Status (12)

Country Link
US (1) US10813980B2 (enExample)
EP (1) EP3468582A1 (enExample)
JP (1) JP7010934B2 (enExample)
KR (1) KR20190018466A (enExample)
CN (1) CN109862905A (enExample)
AU (1) AU2017277747A1 (enExample)
BR (1) BR112018075613A2 (enExample)
CA (1) CA3026984A1 (enExample)
IL (1) IL263564B (enExample)
MA (1) MA45227A (enExample)
RU (1) RU2018145945A (enExample)
WO (1) WO2017212057A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785661A (zh) * 2018-07-20 2018-11-13 深圳市第二人民医院 一种无副作用治疗退行性骨关节病的注射剂及其制备方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102856432B1 (ko) 2022-02-23 2025-09-08 중앙대학교 산학협력단 졸참나무 잎 추출물을 유효성분으로 포함하는 골관절염 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1208760B (it) * 1986-11-04 1989-07-10 Ind Farmaceutica Serono S P A Trattamento delle malattie infiammatorie articolari
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US20040127402A1 (en) * 2002-12-27 2004-07-01 Vad Vijay B. Injectible composition and method for treating degenerative animal joints
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20070184015A1 (en) 2006-02-03 2007-08-09 Soonkap Hahn Novel PEGylation agent
WO2010105685A1 (en) 2009-03-19 2010-09-23 Universite Pierre Et Marie Curie Peptides for inhibiting igf-1
EP2502632B1 (en) 2009-11-18 2016-12-28 Asahi Kasei Pharma Corporation Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis

Also Published As

Publication number Publication date
EP3468582A1 (en) 2019-04-17
WO2017212057A1 (en) 2017-12-14
IL263564B (en) 2021-07-29
BR112018075613A2 (pt) 2019-04-09
US10813980B2 (en) 2020-10-27
JP7010934B2 (ja) 2022-02-10
RU2018145945A3 (enExample) 2020-07-10
JP2019522046A (ja) 2019-08-08
US20190298808A1 (en) 2019-10-03
MA45227A (fr) 2019-04-17
IL263564A (en) 2019-02-03
CN109862905A (zh) 2019-06-07
KR20190018466A (ko) 2019-02-22
CA3026984A1 (en) 2017-12-14
AU2017277747A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
JP2018504901A5 (enExample)
CA2846598C (en) Treatment of degenerative joint disease
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
RU2019126232A (ru) Пептиды и способы для лечения диабета
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
MX2017016844A (es) Composiciones y procedimientos para tratar cancer.
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
CN106604915A (zh) 关节病症的治疗
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
JP2025121987A (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
JP2018505153A5 (enExample)
WO2022177878A1 (en) Glucagon-like peptide-1 receptor antagonists
JP2019522046A5 (enExample)
EP4262746A1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
JP2008543961A5 (enExample)
NZ723300A (en) Compositions for the prevention and/or treatment of pathologies associated with alpha-glucosidase
RU2012100241A (ru) Лечение хориоидальной неоваскуляризации с помощью вакцин
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
RU2019135294A (ru) Полипептид, композиция, фармацевтическая композиция, лекарственное средство, диетическая добавка, пищевая композиция, применения полипептида, фармацевтической композиции, лекарственного средства, диетической добавки, пищевой композиции для лечения ожирения и снижения веса
EP4676944A1 (en) Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
TW202611070A (zh) 用於抗N3pGlu類澱粉β抗體之調配物

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201019

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20210803

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220117